Gene Test Highly Accurate in Predicting Metastasis in Patients with Thymoma
Patients diagnosed with thymoma, a rare cancer of the thymus gland, may be able to avoid certain cancer treatments associated with severe adverse events if the results of a new test reveal they are at low risk of metastasis, according to a study published in PLOS ONE. The study, by researchers at the Indiana University School of Medicine, reported results on a gene-expression profile test designed to predict whether thymoma will metastasize within 5 years.
"Our studies established and validated a nine-gene signature which predicts the likelihood of metastasis more accurately than traditional staging methods, including Masaoka and extent of surgical resection," commented lead study author Sunil Badve, MD, FRCPath, Professor of Pathology and Laboratory Medicine at Indiana University School of Medicine. "Since current guidelines recommend adjuvant radiation and chemotherapy for all resected patients with stage II/III thymoma tumors, it can lead to undertreatment of patients with aggressive tumors diagnosed at an early stage, and overtreatment of slow-growing tumors diagnosed at a later stage."
Patrick J. Loehrer Sr, MD, Director of the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis, commented, “The real secret to the management of rare tumors is a better understanding of their biology. This is a first step in having a clinically meaningful tool for thymoma patients.”
Study Results
In the study, multi-institutional archival primary thymoma tumors were analyzed in a training set (N = 36), and subsequently validated in an independent, multi-institutional cohort of patients (N = 75). In the training set, 10-year metastasis-free survival rates were 77% and 26% for patients with predicted low risk for metastasis (class 1) and those with high risk for metastasis (class 2) (P = .0047, log rank), respectively. For the validation set, 5-year metastasis-free survival rates were 97% and 30% for the low-risk patients (class 1) and high-risk patients (class 2) (P = .0004, log rank), respectively.
Traditional staging includes use of Masaoka stages and extent of surgical resection. Five-year metastasis-free survival rates for the validation set were 49% and 41% for Masaoka stages I/II and III/IV (P = .0537, log rank), respectively. Five-year metastasis-free survival rates for the validation set were 56% and 29% for extent of resection with no evidence of disease and residual disease (P = .0081, log rank).
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
